Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma

M. Santoni, U. De Giorgi, R. Iacovelli, A. Conti, L. Burattini, L. Rossi, S. Luca Burgio, R. Berardi, G. Muzzonigro, E. Cortesi, D. Amadori, S. Cascinu

Research output: Contribution to journalArticlepeer-review

Abstract

Background:Everolimus is a mammalian target of rapamycin inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between pre-treatment neutrophil-to-lymphocyte ratio (NLR) and the outcome of patients treated with everolimus for mRCC.Methods:Ninety-seven patients with mRCC were treated with everolimus till April 2013 in our institutions. Patients were stratified in two groups with NLR >3 (Group A) vs

Original languageEnglish
Pages (from-to)1755-1759
Number of pages5
JournalBritish Journal of Cancer
Volume109
Issue number7
DOIs
Publication statusPublished - Oct 1 2013

Keywords

  • everolimus
  • mTOR inhibitors
  • neutrophil-tolymphocyte ratio
  • renal cell carcinoma
  • targeted therapy
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this